AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04107909 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic cholecystectomy
Description: Both four port and three port LC is performed With the patient in supine position, with the surgeon and assistant on the left side and the monitor on the right side. Head up and right up position is employed during surgery in both the groups. Pneumoperitoneum of 12mmHg is created using open Hassan's method through the umbilical port.~In 3 port a 5.5 mm umbilical visiport for 5 mm lens 30 degree A second 10 mm trocar is placed inferior to the sternum at the midline, while the third 5mm trocar is placed 4-5cm inferior to the right costal margin on the right midclavicular line. For the four port LC, additional 5mm port is placed in the sub costal region at the anterior axillary line. Posterior dissection and delineation of The Calot's triangle is done. Then, the cystic artery and cystic duct are identified, isolated, doubly clipped and divided. The gallbladder is removed through the umbilical port using a 10mm gallbladder extractor.
Study NCT02890784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dasatinib (SPRYCEL®)
Description: Treatment optimization for patients with chronic myeloid leukemia (CML)
Study NCT02890784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib (SPRYCEL®)
Description: Treatment optimization for patients with chronic myeloid leukemia (CML)
Study NCT01897805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heart-protecting Musk Pill
Study NCT01897805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01765335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICaS system
Description: NICaS parameters (cardiac output and total peripheral resistance) and serum BNP levels will be processed in an excel sheet including study reference number to keep confidentiality
Study NCT04660279 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dynamic Whole-Body parametric PET/CT
Description: Dynamic whole-body PET/CT imaging protocol
Study NCT01034956 — intervention group
Intervention type: DEVICE
Intervention: hyaluronic acid or calcium hydroxylapatite filler
Description: Intradermal and subdermal injection of facial soft tissue filler within the past 24 months; survey of patients to assess satisfaction and determine the presence of treatment related adverse events.
Study NCT04615650 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment
Description: Surgical treatment of suprasyndesmotic ankle fractures
Study NCT04615650 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle orthosis
Description: Non-surgical treatment of suprasyndesmotic ankle fractures
Study NCT03810040 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 140 microns denuding pipette
Description: the degranulated needle size was 140 microns
Study NCT03810040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 150 microns denuding pipette
Description: the degranulated needle size was 150 microns
Study NCT02904941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amniotic Membrane Dressing
Description: Amniotic membrane dressings will be made out of donated amniotic membranes from elective cesarean sections. Screening for relevant infectious diseases and irradiation will be performed from every included sample in order to minimise infectious risks. Dressings will be provided to attending surgeons during wound care at the operating theatre and removed every 72-96 hours.
Study NCT02904941 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic Dressing
Description: Silicone dressings will used as an active comparator in this study. As with the amniotic membrane, dressings will be applied to wound care at the operating room and replaced every 72 to 96 hours.
Study NCT02904941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Wound Care
Description: Every included participant will receive standard wound care regardless of treatment allocation. Contaminants such as clothes or other materials will be removed, and all burns will be cleaned using sterile saline solutions. Clorhexidine will also be used to clean the skin. Surgical debridement under general anesthesia or procedural sedation/analgesia will be performed to every included participant, in which nonviable tissues and blisters will be removed.
Study NCT02904941 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Wound Care
Description: Every included participant will receive standard wound care regardless of treatment allocation. Contaminants such as clothes or other materials will be removed, and all burns will be cleaned using sterile saline solutions. Clorhexidine will also be used to clean the skin. Surgical debridement under general anesthesia or procedural sedation/analgesia will be performed to every included participant, in which nonviable tissues and blisters will be removed.
Study NCT00537511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Study NCT00537511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT00537511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT02567877 — intervention group
Intervention type: PROCEDURE
Intervention: thyroidectomy
Description: Patients enrolled in the study will undergo a clinically-indicated thyroidectomy performed as standard of care.
Study NCT02567877 — intervention group
Intervention type: DRUG
Intervention: levothyroxine in thyroidectomy patients
Description: Patients will initiate levothyroxine treatment after surgery consistent with standard of care. The drug dosage will be titrated to TSH goal that matches the pre-surgery TSH (+/- 1 mIU/L)
Study NCT02066129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone 220 mcg
Description: Fluticasone is an inhaled corticosteroid
Study NCT05044624 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: retroperitoneal mass excision
Description: retroperitoneal mass excision
Study NCT02220751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-surgical periodontal therapy + systemic doxycycline
Description: A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.~Non-surgical periodontal therapy was associated with systemic doxycycline 100 mg/day, for two weeks after an initial dose of 200 mg, started on the day before the first scaling and root planning session. Patients of the PD group had no access to information about antibiotics administration to patients of the PD+DM group.
Study NCT02220751 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non-surgical periodontal therapy
Description: A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.
Study NCT00273845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: One session
Study NCT00273845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengths-Based Case Management
Description: 5 sessions
Study NCT03090347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overconsumption of specific dietary nutrient
Description: Subjects will be studied before and then after the consumption of a diet where specific nutrients are provided in excess.
Study NCT04463849 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection
Description: All participants will be subjected to the collection of glycemic data through continuous professional retrospective monitoring of blood glucose for seven days, positioned on the day the test will be performed. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.~The evaluation of insulin secretion will be evaluated by performing the stimulus test with arginine infusion according to validated protocols.
Study NCT04463849 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection
Description: All participants will be subjected to the collection of glycemic data through continuous professional retrospective monitoring of blood glucose for seven days, positioned on the day the test will be performed. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.~The evaluation of insulin secretion will be evaluated by performing the stimulus test with arginine infusion according to validated protocols.
Study NCT03444454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VRRS Khymeia
Description: Participants will receive an individualized exercise program set up by the therapist. The intervention applied to the experimental group will consist of 30 sessions of Khymeia VRRS training distributed in five sessions for week, each lasting 45 minutes.~Each session is constructed by alternating physical with cognitive activities. The sessions will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions.
Study NCT03444454 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care program
Description: The usual care group will have written, home-based exercise program, provided to them at an initial face-to-face assessment.
Study NCT03444454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VRRS Khymeia plus active tDCS
Description: Participants will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training.~The sessions of VRRS will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions.
Study NCT03444454 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VRRS Khymeia plus placebo tDCS
Description: Participants will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training.~The sessions of VRRS will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions.
Study NCT03828474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide Pill
Description: Acetazolamide pill
Study NCT01443130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Chloroquine tablets contain 300 mg chloroquine base per tablet. Dosages: Chloroquine 1,500 mg base over 3 days twice during pregnancy or Chloroquine 600 mg loading dose followed by 300 mg orally once per week. Intermittant preventative treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34 gestation, 4 weeks apart. Participants randomized to IPTp with chloroquine will require their second and third doses of chloroquine after the initial dose given in the clinic and those assigned to chloroquine chemoprophylaxis will require weekly doses.
Study NCT04656769 — intervention group
Intervention type: PROCEDURE
Intervention: Peridural analgesia
Description: We attempted to evaluate the effectiveness of peridural analgesia through cancer survival and recurrence outcomes.
Study NCT03132038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg, every two weeks, during a maximum of one year
Study NCT01443130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Description: Sulfadoxine-pyrimethamine 3 tablets (1,500 mg sulfadoxine and 75 mg pyrimethamine) twice during pregnancy. Intermittant preventive treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34, 4 weeks apart.
Study NCT00843544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Medicine
Description: Participants assigned to the treatment group will begin in groups of ten. The treatment protocol will consist of six 1-2 hour sessions over a six-week period as follows:~1. Subjects will attend a two-session class on healthy eating focused on reducing inflammation-promoting foods in the diet. All subjects will also be started on fish oil and vitamin C supplements, as well as on a supplement called Kaprex, which is an extract from hops and rosemary with anti-inflammatory action. Supplements willl be provided free of charge. Subjects will be provided with a take home supply to begin using.~2. Subjects will attend two classes at CCHH in yoga breathing techniques and will then be provided with a CD for home study and practice~3. Subjects will attend two guided journaling sessions at CCHH in which subjects will be asked to write for a 30-minute period about the most traumatic or stressful life experience to date.
Study NCT00685373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab (ACZ885)
Description: 6 mL glass vial containing 150 mg lyophilized Canakinumab reconstituted with water for a subcutaneous injection every 8 weeks. Dosage based on body weight.
Study NCT03530085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine was administered at 20mg/m2/day on days -9 to -7.
Study NCT03530085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -5 to -4.
Study NCT03530085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine(Flu)
Description: Fludarabine(Flu) was administered at 30mg/m2/day on days -6 to -3.
Study NCT01039298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence visualization device
Description: The trial will randomize 200 patients - 100 in the control arm (using conventional white light approach).
Study NCT01039298 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluorescence visualization device
Description: The trial will randomize 200 patients - 100 in the FV arm (using FV guided the surgery margin)
Study NCT03191877 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: coffee
Description: Nescafe brand of coffee made by Nestlé, red mug 100 % pure coffee 12083811
Study NCT03191877 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: coffee
Description: Nescafe brand of coffee made by Nestlé, red mug 100 % pure coffee 12083811
Study NCT02880813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion
Description: infusion of nutrients
Study NCT04569994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0363-0845
Description: A single dose administered s.c. (subcutaneously, under the skin)
Study NCT04569994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (NNC0363-0845)
Description: A single dose administered s.c.
Study NCT04569994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Description: A single dose administered s.c.
Study NCT04648800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCG-10 vaccine
Description: The BCG-10 anti-tuberculosis vaccine~* powder and solvent for preparing a suspension for intradermal injections of Vaccinum tuberculosis (BCG) cryodesiccatum;~* lyophilised BCG vaccine~* one dose (0.1 ml) contains 50 micrograms of half-dried mass of BCG mycobacteria, which corresponds to 150,000 - 600,000 of live BCG bacilli- the Brazilian Moreau sub-strain.
Study NCT00777699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL765 (SAR245409)
Description: Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; daily dosing
Study NCT00777699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
Study NCT01872442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib 100mg daily starting at inclusion~If ANC ≤ 1.5.109/L, platelets ≤ 100.0.109/L or lymphocytes > 4.0.109/L at 3 months, dasatinib will be continued alone, and patients will be still followed in the study
Study NCT01872442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-Interferon alpha2b
Description: 30 µg weekly starting month 4- month 21
Study NCT02834286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 100 mg weekly days 1, 7, 14, 21
Study NCT02834286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag 50 mg PO days 1-28
Study NCT02834286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg IV/PO days 1-4
Study NCT00201123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosol Interferon-Gamma
Description: Participants will receive aerosol interferon-gamma.
Study NCT00201123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon-gamma
Description: Patients will receive subcutaneous interferon-gamma
Study NCT00201123 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05504668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Turmeric Brainwave
Description: A multiingredient herbal supplement with Turmeric as its most abundant single ingredient.
Study NCT05504668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turmeric Brainwave
Description: A multiingredient herbal supplement with Turmeric as its most abundant single ingredient.
Study NCT03756831 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Core Stability Assessment
Description: Core Stability Assessment will be consisted of bilateral static balance with open and close eye, right foot balance test, and dynamic balance test.
Study NCT02850900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Survey
Description: Weekly survey will be emailed, subjects should complete them
Study NCT01906112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery for primary breast tumor.
Description: Complete resection of primary breast tumor(Lumpectomy or mastectomy)
Study NCT01378611 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Vagus Nerve Stimulator: Neurocybernetic prothesis NCP, Cyberonics Inc., Webster, TX, USA
Description: The study group is stimulated with the following parameters: Output current 0.25 milliampere (to be ramped up to max. 1.75 milliampere), Pulse width 0.5 milliseconds, Frequency 30 Hz, Duty cycle: 30 sec on 5 min off (duty cycle 10%).
Study NCT01378611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulator: Neurocybernetic prothesis NCP, Cyberonics Inc., Webster, TX, USA
Description: The study group is stimulated with the following parameters: Output current 0.25 milliampere (to be ramped up to max. 1.75 milliampere), Pulse width 0.5 milliseconds, Frequency 30 Hz, Duty cycle: 30 sec on 5 min off (duty cycle 10%).
Study NCT00127335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cellulose placebo vs. atorvastatin
Description: drug
Study NCT00127335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cellulose placebo vs. atorvastatin
Description: drug
Study NCT04047420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF/EVG Insert
Description: TAF/EVG Insert (20/16 mg) administered rectally by study staff
Study NCT00237380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
Study NCT03375372 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Root Planing (S&RP)
Description: dental Scaling and Root Planing and oral hygiene regimen
Study NCT04191785 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: plasmatic NGAl and MRI
Description: Determination of plasma NGAL protein during routine blood test Realization of a reno vesical MRI at 48 hours of inclusion
Study NCT00937443 — intervention group
Intervention type: OTHER
Intervention: Physical Fitness
Description: Does intensity of aerobic walking exercise modify cardiac reparative factors
Study NCT02012686 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: transcutaneous electric nerve stimulation frequency of 100 Hz pulse duration of 200 µs wih stimulation intensity of feeling strong but non-painful paresthesia in the upper trapezius